Clinical Trials Browser

Interventional × Triple Negative Breast Neoplasms × darolutamide × Clear all

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms